about
Potential role of G protein-coupled receptor (GPCR) heterodimerization in neuropsychiatric disorders: a focus on depressionEffect of clozapine on ketamine-induced deficits in attentional set shift task in miceAntidepressant drugs promote the heterodimerization of the dopamine D2 and somatostatin Sst5 receptors--fluorescence in vitro studies.Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome levelChronic mild stress alters the somatostatin receptors in the rat brain.Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs.Norepinephrine transporter (NET) knock-out upregulates dopamine and serotonin transporters in the mouse brain.Basal prolactin levels in rat plasma correlates with response to antidepressant treatment in animal model of depression.Prolactin and its receptors in the chronic mild stress rat model of depression.Differential stress response in rats subjected to chronic mild stress is accompanied by changes in CRH-family gene expression at the pituitary level.Time-dependent miR-16 serum fluctuations together with reciprocal changes in the expression level of miR-16 in mesocortical circuit contribute to stress resilient phenotype in chronic mild stress - An animal model of depression.Neuronal cell lines transfected with the dopamine D2 receptor gene promoter as a model for studying the effects of antidepressant drugs.Effect of chronic mild stress and imipramine on the proteome of the rat dentate gyrus.Effect of repeated treatment with reboxetine on the central alpha 1-adrenergic and dopaminergic receptors.Effect of joint administration of imipramine and amantadine on binding of [3H]7-OH-DPAT to dopamine D3 receptors in peripheral blood lymphocytes of the patients with drug-resistant unipolar depression.The effect of combined treatment with imipramine and amantadine on the behavioral reactivity of central alpha1-adrenergic system in rats.Effect of two behavioral tests on corticosterone level in plasma of mice lacking the noradrenaline transporter.Effect of citalopram in the modified forced swim test in rats.Effects of imipramine on cytokines panel in the rats serum during the drug treatment and discontinuation.Stathmin reduction and cytoskeleton rearrangement in rat nucleus accumbens in response to clozapine and risperidone treatment - Comparative proteomic study.Antidepressants promote formation of heterocomplexes of dopamine D2 and somatostatin subtype 5 receptors in the mouse striatum.Life-long norepinephrine transporter (NET) knock-out leads to the increase in the NET mRNA in brain regions rich in norepinephrine terminals.Norepinephrine transporter knock-out alters expression of the genes connected with antidepressant drugs action.Effect of desipramine on gene expression in the mouse frontal cortex - microarray study.Clozapine influences cytoskeleton structure and calcium homeostasis in rat cerebral cortex and has a different proteomic profile than risperidone.Effects on brain-derived neurotrophic factor signalling of chronic mild stress, chronic risperidone and acute intracranial dopamine receptor challenges.Regulation of somatostatin receptor 2 in the context of antidepressant treatment response in chronic mild stress in rat.Clozapine administered repeatedly following pretreatment with ketamine enhances dopamine D2 receptors in the dopamine mesolimbic pathway in mice brain.Understanding GPCR dimerization.Paroxetine and Low-dose Risperidone Induce Serotonin 5-HT1A and Dopamine D2 Receptor Heteromerization in the Mouse Prefrontal Cortex.
P50
Q26823350-2E5DB2E2-A6ED-40F6-9C3E-FAE4BCDD31B9Q33841881-0270774E-9400-4502-89B4-3EA4BF9DE0E3Q34660962-11A35C06-1FD5-4FD8-8429-E4FBED3DEDB6Q36223676-76AC2297-2664-4385-9AFD-336AB306EE09Q36427074-07FEB327-B351-4D33-B489-0A4ECC06AB8FQ38189564-F1E86FEC-AC01-4CD8-AC46-70EBDE1CE35FQ38334086-BABBB451-9790-4108-871F-D54BD1E7B05EQ38881298-CE111090-1166-47D6-8BDB-E8C24764A762Q39261959-29F0F8AD-0B07-437A-A8A2-AAC2B9C2901AQ39268827-F71B2B72-9466-4F28-A359-3DF7ED6475F2Q39284543-D7FDF3B7-8876-4504-8ABD-CEF80BFF3CC5Q40521009-805426E1-100E-4AF5-BC56-B052D6E201F7Q43151643-DEF1797B-DD87-41E9-AF91-FEF9E4A1BA29Q44515585-2BD43330-825F-47B0-B2EC-0F5E9B262270Q44515628-83169205-E7B6-412A-9E05-664818B27694Q44851295-81E93B6A-402F-484D-B300-B4A6F10F5779Q46124477-7F8C2487-E480-4772-8313-262C7004597AQ46808043-3652B7F6-4706-4CD0-8342-261136AB1527Q47382159-011CA2CC-F7A3-48A9-9EB4-ED4375CFFA04Q47585603-D274CAE1-968C-4CE7-8A81-2FDEF4F9FD65Q47683376-C4DFC638-8DC5-4323-B88D-B6E238EC3238Q48163573-537563F2-7E8E-4B0F-8DD2-F022000C7496Q48164340-5FA3C9EB-0C03-46DF-B47E-27A42BDDC4DDQ48311987-2D973102-5663-4608-9C1F-F13444A6C0C3Q48423771-31EFD1EC-B389-45A5-9FD0-043BA9190DAFQ52656192-13A57D7E-3920-4CF9-B1A2-01F1C306108CQ55498448-E1781698-38AB-4420-9F0F-E38A2D0A4A25Q67463428-4D862AEA-3CEC-4E7D-B0BE-E378E53CA0ACQ67496297-5181F78F-F3EE-47D3-ACE0-0B70B9CA680CQ67874154-BD419367-93C6-4B64-8A9C-9EA9D7AD90CE
P50
description
Polish pharmacologist
@en
Pools farmacologe
@nl
polska farmakolog
@pl
name
Joanna Solich
@ast
Joanna Solich
@ca
Joanna Solich
@cs
Joanna Solich
@en
Joanna Solich
@es
Joanna Solich
@gl
Joanna Solich
@hr
Joanna Solich
@hsb
Joanna Solich
@it
Joanna Solich
@nl
type
label
Joanna Solich
@ast
Joanna Solich
@ca
Joanna Solich
@cs
Joanna Solich
@en
Joanna Solich
@es
Joanna Solich
@gl
Joanna Solich
@hr
Joanna Solich
@hsb
Joanna Solich
@it
Joanna Solich
@nl
prefLabel
Joanna Solich
@ast
Joanna Solich
@ca
Joanna Solich
@cs
Joanna Solich
@en
Joanna Solich
@es
Joanna Solich
@gl
Joanna Solich
@hr
Joanna Solich
@hsb
Joanna Solich
@it
Joanna Solich
@nl
P106
P1412
P1559
Joanna Solich
@pl
P21
P214
318144782714036875868
P27
P31
P3124
P734
P735
P7859
viaf-318144782714036875868